116.65
price up icon0.14%   0.16
after-market After Hours: 116.65
loading
Novartis Ag Adr stock is traded at $116.65, with a volume of 1.15M. It is up +0.14% in the last 24 hours and up +5.99% over the past month. Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
See More
Previous Close:
$116.49
Open:
$117.24
24h Volume:
1.15M
Relative Volume:
0.93
Market Cap:
$236.17B
Revenue:
$48.86B
Net Income/Loss:
$16.18B
P/E Ratio:
31.36
EPS:
3.72
Net Cash Flow:
$11.72B
1W Performance:
-3.51%
1M Performance:
+5.99%
6M Performance:
+13.65%
1Y Performance:
+19.16%
1-Day Range:
Value
$116.62
$117.60
1-Week Range:
Value
$116.33
$119.44
52-Week Range:
Value
$92.19
$120.92

Novartis Ag Adr Stock (NVS) Company Profile

Name
Name
Novartis Ag Adr
Name
Phone
-
Name
Address
-
Name
Employee
76,057
Name
Twitter
@novartis
Name
Next Earnings Date
2024-07-18
Name
Latest SEC Filings
Name
NVS's Discussions on Twitter

Novartis Ag Adr Stock (NVS) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-05-24 Downgrade Goldman Buy → Neutral
Sep-03-24 Downgrade Jefferies Buy → Hold
Jul-19-24 Downgrade Deutsche Bank Buy → Hold
May-30-24 Initiated Goldman Buy
Feb-23-24 Initiated BMO Capital Markets Market Perform
Jan-23-24 Initiated Morgan Stanley Equal-Weight
Jan-16-24 Resumed UBS Buy
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Sep-25-23 Upgrade Morgan Stanley Underweight → Equal-Weight
Jul-14-23 Initiated HSBC Securities Buy
Apr-26-23 Upgrade Deutsche Bank Hold → Buy
Mar-27-23 Upgrade Deutsche Bank Sell → Hold
Jan-26-23 Downgrade Citigroup Buy → Neutral
Dec-05-22 Upgrade Stifel Hold → Buy
Sep-15-22 Downgrade Credit Suisse Neutral → Underperform
Sep-14-22 Downgrade Berenberg Buy → Hold
May-09-22 Downgrade Wolfe Research Outperform → Peer Perform
Jan-10-22 Resumed Citigroup Buy
Dec-14-21 Downgrade Redburn Buy → Neutral
Dec-06-21 Downgrade Exane BNP Paribas Outperform → Neutral
Dec-03-21 Downgrade Bryan Garnier Buy → Neutral
Sep-20-21 Downgrade Deutsche Bank Hold → Sell
Mar-22-21 Initiated Bernstein Mkt Perform
Mar-10-21 Downgrade Argus Buy → Hold
Feb-01-21 Downgrade Cowen Outperform → Market Perform
Jan-15-21 Initiated Deutsche Bank Buy
Sep-29-20 Initiated Berenberg Buy
Sep-10-20 Upgrade UBS Neutral → Buy
Sep-01-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-15-20 Upgrade Citigroup Neutral → Buy
Mar-10-20 Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20 Downgrade Guggenheim Buy → Neutral
Apr-25-19 Upgrade Guggenheim Neutral → Buy
Apr-25-19 Upgrade Liberum Hold → Buy
Apr-10-19 Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19 Downgrade JP Morgan Neutral → Underweight
Dec-11-18 Resumed Jefferies Buy
Oct-09-18 Initiated Guggenheim Neutral
Sep-10-18 Upgrade BofA/Merrill Underperform → Buy
May-29-18 Downgrade HSBC Securities Buy → Hold
May-25-18 Upgrade Credit Suisse Underperform → Neutral
Jan-25-18 Reiterated Leerink Partners Outperform
Dec-06-17 Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17 Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17 Downgrade Credit Suisse Neutral → Underperform
Mar-09-17 Initiated Liberum Buy
View All

Novartis Ag Adr Stock (NVS) Latest News

pulisher
Sep 05, 2024

Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts - Benzinga

Sep 05, 2024
pulisher
Sep 05, 2024

Pseudarthrosis Treatment Market is Projected to Reach $1.37 Billion at a CAGR 4.6% by 2034 | Fact.MR Report - GlobeNewswire Inc.

Sep 05, 2024
pulisher
Sep 04, 2024

Market Insight: Novartis AG ADR (NVS)’s Notable Drop, Closing at 118.50 - The Dwinnex

Sep 04, 2024
pulisher
Sep 03, 2024

Weekly Upgrades and Downgrades - InvestorPlace

Sep 03, 2024
pulisher
Sep 03, 2024

Weekly Upgrades and Downgrades - MSN

Sep 03, 2024
pulisher
Sep 02, 2024

Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030 - GlobeNewswire Inc.

Sep 02, 2024
pulisher
Sep 02, 2024

Regenerative Medicine Market Report 2024 - GlobeNewswire Inc.

Sep 02, 2024
pulisher
Sep 02, 2024

Impetigo Drugs Global Strategic Business Report 2024 - GlobeNewswire Inc.

Sep 02, 2024
pulisher
Aug 30, 2024

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology - GlobeNewswire Inc.

Aug 30, 2024
pulisher
Aug 29, 2024

Respiratory Drugs - GlobeNewswire Inc.

Aug 29, 2024
pulisher
Aug 28, 2024

Cell and Gene Therapy Market Size to Achieve USD 117.46 Bn By 2034 - GlobeNewswire Inc.

Aug 28, 2024
pulisher
Aug 27, 2024

Biologics Market Size to Surge to USD 855.8 Billion by 2031 with a 6.9% CAGR, Fueled by Advanced Targeting of Biological Pathways – Report by Transparency Market Research, Inc. - GlobeNewswire Inc.

Aug 27, 2024
pulisher
Aug 27, 2024

By 2034, CAR-T Cell Therapy Market Set to Soar USD 8.7 Billion, at 1.80% CAGR: Prophecy Market Insights - GlobeNewswire Inc.

Aug 27, 2024
pulisher
Aug 26, 2024

Multiple Sclerosis (MS) Diagnosis and Treatment Market Size to Reach USD 30.28 Bn by 2032 - GlobeNewswire Inc.

Aug 26, 2024
pulisher
Aug 23, 2024

Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - GlobeNewswire Inc.

Aug 23, 2024
pulisher
Aug 23, 2024

Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - GlobeNewswire Inc.

Aug 23, 2024
pulisher
Aug 22, 2024

Targeted Therapeutics Market is Pioneering Growth Towards a USD 118.6 Billion Milestone by 2031, with a CAGR of 6.4% - GlobeNewswire Inc.

Aug 22, 2024
pulisher
Aug 22, 2024

Ex-Chinook team launches Borealis Biosciences with $150-million from Novartis, Versant - The Globe and Mail

Aug 22, 2024
pulisher
Aug 22, 2024

Solid Organ Transplant Market is Projected to Grow at a 4.9% CAGR, Reaching $7.88 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.

Aug 22, 2024
pulisher
Aug 21, 2024

Strategic Opportunities in Thin Film Drug Manufacturing Market to Expand to USD 16.5 Billion by 2034, Driving Industry Growth | Transparency Market Research Inc. - GlobeNewswire Inc.

Aug 21, 2024
pulisher
Aug 20, 2024

UK Patient's Perspective on the Corporate Reputation of Pharma, 2023-2024 - GlobeNewswire Inc.

Aug 20, 2024
pulisher
Aug 20, 2024

Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy - Barchart

Aug 20, 2024
pulisher
Aug 20, 2024

Cancer Immunotherapy Market Size Expected to Touch USD 530.2 Billion by 2034, With 14.2% CAGR Growth: Prophecy Market Insights - GlobeNewswire Inc.

Aug 20, 2024
pulisher
Aug 19, 2024

mTOR (Mammalian Target of Rapamycin) Inhibitors Strategic Research Report 2024: Expanding Applications Beyond Cancer Treatment - GlobeNewswire Inc.

Aug 19, 2024
pulisher
Aug 16, 2024

Market Recap Check: Novartis AG ADR (NVS)’s Negative Finish at 113.31, Up/Down -0.19 - The Dwinnex

Aug 16, 2024
pulisher
Aug 15, 2024

Is the European Stock Market Too Concentrated? - Morningstar

Aug 15, 2024
pulisher
Aug 12, 2024

Monoclonal Antibodies Market Size is Surpassing USD 650.49 Billion by 2033, Growing at Projected 12.0% CAGR - GlobeNewswire Inc.

Aug 12, 2024
pulisher
Aug 12, 2024

Why GRANOLAS Performance Has Been So Patchy - Morningstar

Aug 12, 2024
pulisher
Aug 12, 2024

Attention-Deficit Hyperactivity Disorder Treatment Market is projected to Reach USD 15.4 Billion, Garnering A 3.1% CAGR from 2024 to 2034 | Report Analysis by Transparency Market Research Inc. - GlobeNewswire Inc.

Aug 12, 2024
pulisher
Aug 08, 2024

Active Pharmaceutical Ingredients Market Size Worth $421.56 Billion by 2033: The Brainy Insights - GlobeNewswire Inc.

Aug 08, 2024
pulisher
Aug 07, 2024

Antibody Production Market to Surpass USD 36.49 Billion by 2032 Driven by Escalating Demand for Targeted Therapies and Technological Advancements | Research by SNS Insider - GlobeNewswire Inc.

Aug 07, 2024
pulisher
Aug 06, 2024

Biotechnology Market Size and Growth | USD 4.25 Trillion by 2033 - GlobeNewswire Inc.

Aug 06, 2024
pulisher
Aug 01, 2024

Cervical Spondylosis Diagnosis and Treatment Market Size to Reach USD 6.30 Bn by 2032 - GlobeNewswire Inc.

Aug 01, 2024
pulisher
Jul 30, 2024

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss? - Yahoo Canada Finance

Jul 30, 2024
pulisher
Jul 30, 2024

Global Regenerative Medicine Market Size To Worth USD 349.93 Billion By 2033 | CAGR of 27.06% - GlobeNewswire Inc.

Jul 30, 2024
pulisher
Jul 25, 2024

10 Stocks to Watch From the Best International Fund Managers - Morningstar

Jul 25, 2024
pulisher
Jul 24, 2024

Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings? - Zacks Investment Research

Jul 24, 2024
pulisher
Jul 23, 2024

AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife - Benzinga

Jul 23, 2024
pulisher
Jul 23, 2024

Berenberg raises Novartis shares target on growth outlook - Investing.com

Jul 23, 2024
pulisher
Jul 22, 2024

Global Consumer Health Market Size To Worth USD 713.92 Billion By 2033 | CAGR Of 7.34% - GlobeNewswire Inc.

Jul 22, 2024
pulisher
Jul 19, 2024

Pharma Leader Beats on Earnings, But Shares Fall - sharewise

Jul 19, 2024
pulisher
Jul 19, 2024

Wipro Ltd. ADR [WIT] Revenue clocked in at $10.84 billion, up 23.70% YTD: What’s Next? - The DBT News

Jul 19, 2024
pulisher
Jul 19, 2024

Invitation Homes Inc [INVH] Stock trading around $35.92 per share: What’s Next? - The DBT News

Jul 19, 2024
pulisher
Jul 19, 2024

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data - Zacks Investment Research

Jul 19, 2024
pulisher
Jul 19, 2024

Bank Of Nova Scotia [BNS] is -2.79% lower this YTD. Is it still time to buy? - The DBT News

Jul 19, 2024
pulisher
Jul 18, 2024

Why Novartis Stock Is Down Today Despite Topping Q2 Estimates - sharewise

Jul 18, 2024
pulisher
Jul 18, 2024

Novartis AG ADR’s Shares Reel: 15.12% Quarterly Revenue Decline Amid 209.64B Market Cap - The InvestChronicle

Jul 18, 2024
pulisher
Jul 18, 2024

Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View - Zacks Investment Research

Jul 18, 2024
pulisher
Jul 18, 2024

Ophthalmology research at Novartis - Novartis

Jul 18, 2024
pulisher
Jul 18, 2024

Neuroscience research at Novartis - Novartis

Jul 18, 2024
pulisher
Jul 18, 2024

Global Health disease area research at Novartis - Novartis

Jul 18, 2024

Novartis Ag Adr Stock (NVS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general MRK
$117.84
price down icon 0.63%
$320.56
price down icon 1.17%
drug_manufacturers_general PFE
$28.56
price up icon 0.18%
drug_manufacturers_general SNY
$57.73
price down icon 0.88%
$193.40
price up icon 0.28%
Cap:     |  Volume (24h):